GrantsExplained
Search GrantsCategoriesGuidesAbout
GrantsExplained

Billions in free federal funding you may qualify for.

Explore

  • Search Grants
  • Categories
  • How It Works
  • Pricing
  • About

Guides

  • All Guides
  • Getting Started
  • Reading a Grant Listing

Resources

  • FAQ
  • Simpler.Grants.gov
  • SAM.gov

© 2026 GrantsExplained. Not affiliated with any government agency.

Official grant sources govern all application requirements and eligibility.

ContactTermsPrivacy
Back to Search
Open
RFA-DK-27-147

Single Source for Continuation of the Integrated Islet Distribution Program U24 (Clinical Trial Not Allowed)

National Institutes of Health (HHS-NIH11)

Up to $2,200,000
Due Sep 30, 2026
At a glance
Very Complex

This grant is for continuing support of the Integrated Islet Distribution Program, which helps provide human islets for diabetes research. It's specifically aimed at the Beckman Research Institute/City of Hope to renew their program. The goal is to keep supplying these important resources to researchers working on diabetes prevention and treatment.

Who it's for: This grant is specifically intended for the Beckman Research Institute/City of Hope to continue their work with the Integrated Islet Distribution Program. The program supports diabetes research by distributing human islets to scientists.

More details

Likely Disqualifiers

  • Not being Beckman Research Institute/City of Hope
  • Proposing a clinical trial
  • Submitting after the deadline
  • Not adhering to NIH peer-review standards

What You May Need

  • Detailed project proposal
  • Budget justification
  • NIH peer-review compliance documents
  • Organizational capability statement
  • Letters of support from partners
  • Proof of past performance in islet distribution
  • NIH biosketches for key personnel
  • Human subjects protection plan
  • Data sharing plan

Cautions

  • This is a single source grant for a specific organization.
  • Clinical trials are not allowed under this grant.
  • Strict adherence to NIH peer-review processes is required.
  • Ensure all documents are submitted by the deadline.

Generated from official source details for readability

Eligibility

Eligible Applicant Types

Unrestricted

Additional Criteria

The grant is specifically intended for the Beckman Research Institute/City of Hope to continue the Integrated Islet Distribution Program. This is a single source award, meaning that only this organization is eligible to apply. The program is part of the Special Diabetes Program, which supports innovative research on type 1 diabetes.

Overview

This grant is specifically intended for the Beckman Research Institute/City of Hope to continue their work with the Integrated Islet Distribution Program. The program supports diabetes research by distributing human islets to scientists.

Likely Disqualifiers

  • Not being Beckman Research Institute/City of Hope
  • Proposing a clinical trial
  • Submitting after the deadline
  • Not adhering to NIH peer-review standards

Use of Funds

Funds can be used to support the distribution of human islets for diabetes research, including partnerships with islet isolation facilities. The aim is to advance diabetes research and develop new therapies.

Total Program Funding

$3,300,000

Expected Awards

1

Cost Sharing

Not Required

Important Dates

Posted
May 20, 2026
Deadline
Sep 30, 2026(109 days)
Archive Date
Nov 29, 2026

Application Checklist

0/6 complete
  • Verify eligibility as Beckman Research Institute/City of Hope
  • Prepare a detailed project proposal
  • Compile budget and justification
  • Gather letters of support
  • Ensure compliance with NIH peer-review standards
  • Submit application by September 30, 2026

Award Range

N/A - $2,200,000

Deadline

Sep 30, 2026

Total Program Funding

$3,300,000

Official Source

Always review the official grant listing for the most accurate and up-to-date information.

View Official Listing

Get free grant alerts

New funding opportunities and eligibility tips, weekly.

Weekly updates. Unsubscribe anytime. No spam.